Regulatory Query for study repeat [Study As­sess­ment]

posted by sam – India, 2013-07-29 14:36 (4718 d 22:57 ago) – Posting: # 11103
Views: 25,145

Dear John,

❝ 1. Similar to what the other gurus have asked, please provide the numbers to us.


Not possible to provide the numbers

❝ 2. Was there a change in the formulation or process? From pilot batch to scale-up batch... Please check because I have seen a few cases from my previous company (and friend's companies) that the issue was related to the manufacturing process. I work closely with formulators these days (small company) and you will be surprised to hear the things that they educate me on...


There was no change in the formulation or process.

❝ 3. Have you checked the PK data in details, both pilot and pivotal. Look for outliers? Don't bother with the post-hoc power business.


I have checked the Pilot and Pivotal data thoroughly.

❝ 4. Any difference in study population between studies?


The study populations are totally different. Pilot are carried out in other CRO and Pivotal in other

❝ 5. Drug has complicated kinetics?


No.

Best Regards
Sam


Edit: Standard quotes restored. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
323 visitors (0 registered, 323 guests [including 16 identified bots]).
Forum time: 13:34 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5